Compositions for therapeutics, targeted PET imaging and methods of their use
Described herein is a chelator for radiolabels (e.g., 89 Zr) for targeted PET imaging that is an alternative to DFO. In certain embodiments, the chelator for 89 Zr is the ligand, 3,4,3-(LI-1,2-HOPO) (“HOPO”), which exhibits equal or superior stability compared to DFO in chemical and biological assays across a period of several days in vivo. As shown in FIG. 1 , the HOPO is an octadentate chelator that stabilizes chelation of radiolabels (e.g., 89 Zr). A bifunctional ligand comprising p-SCN-Bn-HOPO is shown in FIG. 4 and FIG. 5 . Such a bifunctional ligand can eliminate (e.g., 89 Zr) loss from the chelate in vivo and reduce uptake in bone and non-target tissue. Therefore, the bifunctional HOPO ligand can facilitate safer and improved PET imaging with radiolabeled antibodies.
1. A composition comprising:
an oxygen-bearing ligand comprising at least 8 coordination oxygens;
a radiolabel associated with the oxygen-bearing ligand; and
a spacer between the oxygen-bearing ligand and a conjugation functionality;
wherein the conjugation functionality comprises a moiety for association of the oxygen-bearing ligand with a targeting agent; and
wherein the oxygen-bearing ligand, the spacer, and the conjugation functionality together comprise
2. The composition of claim 1 , wherein the composition comprises the targeting agent and wherein the targeting agent is an antibody.
3. The composition of claim 2 , wherein the antibody is a member selected from the group consisting of trastuzumab, rituximab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab tiuxetan, tositumomab, cetuximab, bevacizumab, panitumomab, J591, B43.13, AR9.6, 3F8, 8H9, huA33, and 5B1.
4. The composition of claim 2 , wherein the composition comprises 177 Lu and/or 89 Zr.
5. A method for detecting and/or analyzing tumor cells, the method comprising:
administering a quantity of the composition of claim 1 to a subject, wherein a portion of the quantity localizes at the tumor cells; and
imaging the composition accumulated in a region of the subject within a time period no longer than 336 hours from the administering of the quantity of the composition.
6. The method of claim 5 , wherein the tumor cells are cells that express at least one marker of at least one of prostate cancer, lung cancer, adenocarcinoma, adenoma, adrenal cancer, basal cell carcinoma, bone cancer, brain cancer, breast cancer, bronchi cancer, cervical dysplasia, colon cancer, epidermoid carcinoma, Ewing's sarcoma, gallbladder cancer, gallstone tumor, giant cell tumor, glioblastoma multiforma, head cancer, hyperplasia, hyperplastic corneal nerve tumor, in situ carcinoma, intestinal ganglioneuroma, islet cell tumor, Kaposi's sarcoma, kidney cancer, larynx cancer, leiomyoma tumor, liver cancer, malignant carcinoid, malignant hypercalcemia, malignant melanomas, marfanoid habitus tumor, medullary carcinoma, metastatic skin carcinoma, mucosal neuromas, mycosis fungoide, neck cancer, neural tissue cancer, neuroblastoma, osteogenic sarcoma, osteosarcoma, ovarian tumor, pancreas cancer, parathyroid cancer, pheochromocytoma, primary brain tumor, rectum cancer, renal cell tumor, retinoblastoma, rhabdomyosarcoma, seminoma, skin cancer, small-cell lung tumor, soft tissue sarcoma, squamous cell carcinoma, stomach cancer, thyroid cancer, topical skin lesion, veticulum cell sarcoma, Wilm's tumor, or combinations thereof.
7. The method of claim 5 , wherein administering comprises injecting the quantity of the composition to the subject.
8. The method of claim 5 , wherein the imaging is performed via positron emission tomography (PET) imaging.
9. The method of claim 5 , wherein the composition comprises at least one europium(III) ion.
10. The method of claim 9 , wherein imaging the composition comprises
directing light to excite at least one group in the oxygen-bearing ligand of the composition; and
detecting light emitted from the at least one europium(III) and/or other lanthanide ion.
11. The method of claim 10 , wherein the directed light has a wavelength from 300 nm to 400 nm.
12. The method of claim 10 , wherein the detected light comprises light in the visible and/or near infrared range.
13. The composition of claim 1 , wherein the radiolabel is selected from the group consisting of 89 Zr, 44 Sc, 47 Sc, 68 Ga, 177 Lu, 227 Th, 166 Ho, 90 Y, 153 Sm, 149 Pm, 161 Tb, 169 Er, 175 Yb, 161 Ho, 167 Tm, 142 Pr, 143 Pr, 145 Pr 149 Pr, 150 Eu, 159 Gd, 165 Dy, 176m Lu, 179 Lu, 142 La, 150 Pm, 156 Eu, 157 Eu, and 225 Ac.
14. The composition of claim 1 , wherein the composition comprises a plurality of radiolabels.
15. A method for detecting tumor cells, analyzing tumor cells, or both detecting and analyzing tumor cells, the method comprising:
injecting a quantity of the composition of claim 2 to a subject, wherein a portion of the quantity localizes at the tumor cells; and
imaging the composition accumulated in a region of the subject within a time period no longer than 336 hours from the administering of the quantity of the composition.
16. The method of claim 15 , wherein the antibody is a member selected from the group consisting of trastuzumab, rituximab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab tiuxetan, tositumomab, cetuximab, bevacizumab, panitumomab, J591, B43.13, AR9.6, 3F8, 8H9, huA33, and 5B1.
17. The method of claim 15 , wherein the radiolabel is selected from the group consisting of 89 Zr, 44 Sc, 47 Sc, 68 Ga, 177 Lu, 227 Th, 166 Ho, 90 Y, 153 Sm, 149 Pm, 161 Tb, 169 Er, 175 Yb, 161 Ho, 167 Tm, 142 Pr, 143 Pr, 145 Pr, 149 Pr, 150 Eu, 159 Gd, 165 Dy, 176m Lu, 179 Lu, 142 La, 150 Pm, 156 Eu, 157 Eu, and 225 Ac.
18. The method of claim 15 , wherein the tumor cells are cells that express at least one marker of at least one of prostate cancer, lung cancer, adenocarcinoma, adenoma, adrenal cancer, basal cell carcinoma, bone cancer, brain cancer, breast cancer, bronchi cancer, cervical dysplasia, colon cancer, epidermoid carcinoma, Ewing's sarcoma, gallbladder cancer, gallstone tumor, giant cell tumor, glioblastoma multiforma, head cancer, hyperplasia, hyperplastic corneal nerve tumor, in situ carcinoma, intestinal ganglioneuroma, islet cell tumor, Kaposi's sarcoma, kidney cancer, larynx cancer, leiomyoma tumor, liver cancer, malignant carcinoid, malignant hypercalcemia, malignant melanomas, marfanoid habitus tumor, medullary carcinoma, metastatic skin carcinoma, mucosal neuromas, mycosis fungoide, neck cancer, neural tissue cancer, neuroblastoma, osteogenic sarcoma, osteosarcoma, ovarian tumor, pancreas cancer, parathyroid cancer, pheochromocytoma, primary brain tumor, rectum cancer, renal cell tumor, retinoblastoma, rhabdomyosarcoma, seminoma, skin cancer, small-cell lung tumor, soft tissue sarcoma, squamous cell carcinoma, stomach cancer, thyroid cancer, topical skin lesion, veticulum cell sarcoma, Wilm's tumor, or combinations thereof.
19. The method of claim 18 , wherein the antibody is a member selected from the group consisting of trastuzumab, rituximab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab tiuxetan, tositumomab, cetuximab, bevacizumab, panitumomab, J591, B43.13, AR9.6, 3F8, 8H9, huA33, and 5B1.
20. The method of claim 19 , wherein the radiolabel is selected from the group consisting of 89 Zr, 44 Sc, 47 Sc, 68 Ga, 177 Lu, 227 Th, 166 Ho, 90 Y, 153 Sm, 149 Pm, 161 Tb, 169 Er, 175 Yb, 161 Ho, 167 Tm, 142 Pr, 143 Pr, 145 Pr, 149 Pr, 150 Eu 159 Gd, 165 Dy, 176m Lu, 179 Lu, 142 La, 150 Pm, 156 Eu, 157 Eu, and 225 Ac.
21. The method of claim 15 , wherein the imaging is performed via positron emission tomography (PET) imaging.
22. The method of claim 15 , wherein
the composition comprises at least one europium(III) ion; and
wherein imaging the composition comprises
directing light has a wavelength from 300 nm to 400 nm to excite at least one group in the oxygen-bearing ligand of the composition; and
detecting visible light, near infrared light, or both, emitted from the at least one europium(III) ion.